About type 2 diabetes

Type 2 diabetes is a metabolic disorder characterized by hyperglycemia resulting from inadequate insulin secretion or insulin resistance. The most common form of diabetes, it represents 90% of all cases. Often referred to as a pandemic, it is estimated that over 400 million people worldwide are affected by diabetes, with management costs exceeding $800 billion annually.

About DIAMOND therapy

DIAMOND therapy is delivered via an implantable medical device which has the potential to be used as an alternative to insulin.  The safety and efficacy of DIAMOND therapy have been validated in clinical trials involving over 300 patients, including a pilot study which demonstrated a comparable effectiveness to insulin treatment, but avoiding many side-effects and the inconvenience of frequent blood tests and injections.  Designed to treat type 2 diabetes in obese patients who are refractory to oral medication, DIAMOND therapy is delivered via a small pacemaker-like device implanted in the abdomen, which delivers electrical signals to the stomach when eating, improving glycemic control and promoting weight loss.  DIAMOND has received CE mark and is approved for sale in Europe, Australia and other international markets; it is currently not approved for use in the USA.  For more information, visit www.MetaCure.com/DIAMOND.

About MetaCure

MetaCure, a member of the Hobart Group companies, aims to provide a better way to manage type 2 diabetes, focusing on the impact on the day-to-day lives of patients.  It develops, produces and markets the DIAMOND therapy, an alternative to insulin delivered via a proprietary implantable device.  For more information, visit www.MetaCure.com.

About Hobart Group

The Hobart Group develops and commercializes medical technologies which target top healthcare markets with significant unmet needs.  Its growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation.  Together, Hobart Group companies have over 200 scientists, engineers, regulatory and business experts across four continents, benefitting from clinical expertise and extensive regulatory and international market knowledge across Europe, the USA and Asia.  For more information, visit www.Hobart-Group.com.

References

[1] American Diabetes Association (ADA). Standards of care in diabetes—2015. Diabetes Care. 2015;38 Suppl:S4.
[2] Ibid.
[3] Lebovitz HE, Yaniv I, Schwartz T, Zelewski M, et al. Treatment of patients with obese type 2 diabetes with Tantalus-DIAMOND® gastric contractility modulation: Normal tryiglycerides predict durable effect for at least 3 years. Horm Metab Res. 2015;47:456-62.
[4] Ibid.
[5] Wong SK, Kong AP, Luk AO, Ozaki R, et al. A pilot study to compare meal-triggered gastric contractility modulation and insulin treatment in Chinese obese type 2 diabetes. Diabetes Technol Ther. 2015;17:283-90.
[6] Policker S, Haddad W, Yaniv I. Treatment of type 2 diabetes using meal-triggered gastric contractility modulation. IMAJ. 2009;11:206-208.
[7] Bohdjalian A, Prager G, Rosak C, Weiner R, et al. Improvement in glycemic control in morbidly obese type 2 diabetic subjects by gastric stimulation. Obes Surg. 2009;19:1221-1227.
[8] Lebovitz HE, Yaniv I, Schwartz T, Zelewski M, et al. Treatment of patients with obese type 2 diabetes with Tantalus-DIAMOND® gastric contractility modulation: Normal tryiglycerides predict durable effect for at least 3 years. Horm Metab Res. 2015;47:456-62.
[9] American Diabetes Association (ADA). Standards of care in diabetes—2015. Diabetes Care. 2015;38 Suppl:S4.
[10] International Diabetes Federation. IDF Diabetes Atlas, Sixth Edition. 2014 Update.
[11] Astrup A, Finer N. Redefining type 2 diabetes: ‘Diabesity’ or ‘obesity-dependent diabetes mellitus’? Obes Rev. 2000;1:57-9.